Page 9 - Recombinant Informatics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Recombinant informatics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Recombinant Informatics Today - Breaking & Trending Today

Expanded Range of Laminin isoforms

Efficient cell culture and differentiation of ES/iPS cells Designed to efficiently induce differentiation in ES and iPS cells, AMSBIO has expanded its iMatrix series of recombinant laminin E8 fragments to now include isoforms LN-111 and LN-332. Click to read more. ....

Pluripotent Stem Cells , Mesenchymal Stem Cells ,

Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer | Antibodies

Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer ....

United States , Biochim Biophys Acta , Jeff Legos , Global Head Of Oncology Hematology Development , American Joint Committee On Cancer , World Health Organization , American Cancer Society , Union For International Cancer Control , Switzerlandi August , Executive Vice President , Global Head , Hematology Development , American Joint Committee , International Cancer Control , Pro Tumor Inflammation , Tumor Inflammation , Adjuvant Therapy , Adult Subjects With Stages , Clinical Trial Protocol , About Lung , Accessed July , Lung Cancer , Therapeutic Antibodies , Antibody Drug Conjugates , Biosimilar Antibodies , Biosuperior Antibodies ,

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design | Vaccines

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design ....

United States , United Kingdom , I Pfizer Inc , European Union , Strategy With Study Start , Next Generation Vaccine Candidate Based , Enhanced Spike Protein Design , Germanyi July , Marketing Authorization Holder , Emergency Use Authorization , Use Authorization , Coronavirus Disease , Fact Sheets , Prescribing Information , Breakthroughs That Change Patient , Pfizer News , Immune Therapy , Personalized Immunotherapy , Cancer Vaccine ,

SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab) | Proteins and Peptides

SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab) ....

Czech Republic , United States , Richard Sachse , Peter Grell , Merck Co Inc , Merck Sharp Dohme , Gustave Roussy Cancer Center , Masaryk Memorial Cancer Institute , Superagonist Technology , Drug Development , First Patient , Switzerlandi July , Chief Medical Officer , Managing Director , Inpatient Unit , Merck Sharp , Therapeutic Protein , Binding Proteins ,

Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF) | Antibodies

Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF) ....

United States , Keren Haruvi , Abbvie Biotechnology Ltd , Sandoz Inc , Drug Administration , European Medicines Agency , Sandoz Supplemental Biologics License Application , Switzerlandi July , Supplemental Biologics License Application , Idiopathic Arthritis , Abbvie Biotechnology , Therapeutic Antibodies , Antibody Drug Conjugates , Biosimilar Antibodies , Biosuperior Antibodies , Antibody Fragments , Domain Antibodies ,